Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Beta-lapachone Highly Effective Against Non-small Cell Lung Cancer

By Biotechdaily staff writers
Posted on 18 Jul 2007
A recent report described the molecular mechanism used by the chemotherapeutic agent beta-lapachone to kill non-small cell lung cancer (NSCLC) tumors. NSCLC is one of the deadliest forms of cancer with a five-year survival rate of only about 15%.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) studied the action of beta-lapachone on the enzyme NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 is absent or nearly absent in normal tissues but highly expressed in NSCLC tumors.

Results published in the July 3, 2007, online edition of the Proceedings of the [U.S.] National Academy of Sciences revealed that NSCLC cells grown in tissue culture were killed by a high dose of beta-lapachone given for only two to four hours. Normal cells not expressing NQO1 were not damaged by the drug.

Beta-lapachone induced formation of active radicals that caused damage to the cancer cells' DNA while at the same time disrupting the cells' ability to repair their DNA (by inhibiting the DNA repair enzyme topoisomerase I), ultimately leading to the death of the cells. Since treating tumor cells with radiation also causes DNA damage, co-treatment with radiation and beta-lapachone was even more effective than treatment with the drug alone.

"When you irradiate a tumor, the levels of NQO1 go up,” said senior author Dr. David Boothman, professor of pharmacology and radiation oncology at the University of Texas Southwestern Medical Center. "When you then treat these cells with beta-lapachone, you get synergy between the enzyme and this agent and you get a whopping kill. Basically, we have worked out the mechanism of action of beta-lapachone and devised a way of using that drug for individualized therapy.”


Related Links:
University of Texas Southwestern Medical Center

WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Outer membrane vesicles released by Bacteroides thetaiotaomicron may help initiate inflammatory bowel disease (Photo courtesy of Wandy Beatty, Washington University School of Medicine).

Interaction of Gut Cells with Bacterial Outer Membrane Vesicles Triggers Inflammatory Bowel Disease in Mouse Model

Interaction of bacterial outer membrane vesicles (OMVs) harboring sulfatase activity with the cells lining the gut has been implicated as a key step in the development of inflammatory bowel diseases (IBDs)... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.